These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 83968)

  • 61. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effects of syngeneic soluble tumor membrane extract on concomitant spleen cell immunity and spontaneous metastases.
    Temple WJ; Sugarbaker EV; Ketcham AS
    J Surg Res; 1984 Jan; 36(1):71-9. PubMed ID: 6690843
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of immunosuppressor cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma.
    Minami A; Kasai M; Mizushima Y; Takeichi N; Hosokawa M; Kobayashi H
    Cancer Res; 1980 Jul; 40(7):2129-34. PubMed ID: 6446378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pregnancy-induced antitumor cytotoxicity of T cell-rich fraction against mammary adenocarcinoma cells in rats.
    Chakravarty PK; Sinha DK
    Carcinogenesis; 1992 Dec; 13(12):2449-52. PubMed ID: 1473255
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reversal of SV40 tumor-mediated suppression of spleen cell cytotoxicity by antibody.
    Prather SO; Lausch RN
    J Immunol; 1977 Jan; 118(1):203-10. PubMed ID: 187698
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor-specific immunogenicity induced by chemical modification.
    Eggers AE
    J Natl Cancer Inst; 1976 Apr; 56(4):869-70. PubMed ID: 943563
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
    Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M
    J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The immunologic responsiveness of regional lymphocytes in experimental cancer.
    Goldfarb PM; Hardy MA
    Cancer; 1975 Mar; 35(3):778-83. PubMed ID: 1111943
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Induction of "innocent bystander" cytotoxicity in nonimmune mice by adoptive transfer of L3T4+ Lyt-1+2- mammary tumor immune T-cells.
    Paul RD; Lopez DM
    Cancer Res; 1987 Feb; 47(4):1105-10. PubMed ID: 2879623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system.
    Fujiwara H; Hamaoka T; Nishino Y; Kitagawa M
    Gan; 1977 Oct; 68(5):589-601. PubMed ID: 73490
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emergence of a subpopulation of lymphocytes bearing theta antigen and complement receptor during tumor growth.
    Epstein RS; Lopez DM; Ortiz-Muniz G; Sigel MM
    Int J Cancer; 1976 Oct; 18(4):458-61. PubMed ID: 789259
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Frey AB
    J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S; Chou T; Rosenberg SA
    J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction.
    Cohen IR; Stavy L; Feldman M
    J Exp Med; 1970 Dec; 132(6):1055-70. PubMed ID: 5511566
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lymphoreticular cells isolated by centrifugal elutriation from a mammary adenocarcinoma. I. Characterization of an in situ lymphocyte suppressor population by surface markers and functional reactivity.
    Buessow SC; Paul RD; Miller AM; Lopez DM
    Int J Cancer; 1984 Jan; 33(1):79-85. PubMed ID: 6229495
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stimulation of murine lymphocytes by a syngeneic, methylcholanthrene-induced mammary carcinoma.
    Colgrove GS; Shifrine M
    Proc Soc Exp Biol Med; 1974 Apr; 145(4):1317-20. PubMed ID: 4275114
    [No Abstract]   [Full Text] [Related]  

  • 78. In vitro studies on splenocyte cytotoxicity against syngeneic mammary carcinomas of mice. 1. Reactivity of splenocytes from mice bearing mammary tumors against the corresponding and against other neoplasms.
    More R; Yron I; Weiss DW
    Isr J Med Sci; 1978 Jan; 14(1):146-61. PubMed ID: 204609
    [No Abstract]   [Full Text] [Related]  

  • 79. Effects of isolated tumor lymphocytes alone and with adherent cells.
    Blazar BA; Galili N; Klein E
    Cancer Immunol Immunother; 1984; 18(3):179-84. PubMed ID: 6568875
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mouse.
    Yamauchi K; Fujimoto S; Tada T
    J Immunol; 1979 Oct; 123(4):1653-8. PubMed ID: 90095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.